Table 1.
General characteristics of the study participants at baseline.
| Variables | Placebo group (n = 50) | Folic acid group (n = 50) | P-value |
|---|---|---|---|
| Male, n (%) | 23 (46) | 22 (44) | 0.841 |
| Age (years) | 54.46 ± 7.81 | 52.86 ± 9.46 | 0.36 |
| Duration of diabetes (years) | 7.14 ± 3.76 | 7.82 ± 3.94 | 0.38 |
| Hypertension, n (%) | 27 (54) | 23 (46) | 0.424 |
| Hyperlipidemia, n (%) | 14 (28) | 12 (24) | 0.648 |
| Smoker, n (%) | 17 (34) | 15 (30) | 0.668 |
| ACEIs use, n (%) | 19 (38) | 23 (46) | 0.418 |
| ARB use, n (%) | 17 (34) | 21 (42) | 0.410 |
| BB use, n (%) | 7 (14) | 3 (6) | 0.182 |
| CCB use, n (%) | 10 (20) | 11 (22) | 0.806 |
| OHA Co-treatment with Metformin | |||
| Glimepiride, n (%) | 20 (50) | 25 (50) | 0.315 |
| Glibenclamide, n (%) | 18 (36) | 15 (30) | 0.523 |
| Vildagliptin, n (%) | 12 (24) | 10 (20) | 0.629 |
Data presented as number (percentage) or mean ± SD.
ACEIs Angiotensin-converting enzyme inhibitors, ARBs Angiotensin Receptor Blockers, BB Beta-blockers, CCB Calcium channel blocker, OHA Oral hypoglycemic agents.
Data analysed using independent sample t-test or Chi-square as appropriate. Statistically significant between groups at P < 0.05.